Conference abstract · 7 Sep 2017
Conference abstractPublished 17 Aug 2015
Development of non-viral nanoDDS for DNA: Analysis, control of the intracellular trafficking and beyond
Hokkaido University, Japan
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
A category of biomedicine is now expanding from low-molecular drugs to the recombinant protein, antibody, and nucleic acids (i.e. siRNA, mRNA and plasmid DNA). While the gene therapy approach has faced technical and/or regulatory impediments, a large number of clinical trials are still ongoing worldwide. One crucial success is the first approval of the Glybera® (UniQure) by the European Medicinal Agency (EMA) as a first gene-based medication\\r\\nGene expression efficacy is rate-limited by the multiple processes (i.e. cellular uptake, endosomal escape, cytoplasmic transport and nuclear delivery). Adequate design to overcome these barriers is a minimum requirement. Our quantitative and mechanism-based information on differences in transfection efficiency between viral and artificial cationic vectors revealed that post-nuclear delivery processes (i.e. transcription and translation) predominantly contributed to the poor transfection efficacy in artificial ones in dividing cells. In other words, the process of the post-organelle delivery process (intra-organelle disposition) should be taken into the consideration.\\r\\nIn this presentation, I’ll propose two strategies to enhance/maximize these processes. First strategy is to develop a neutral nanoparticle in those the use of the cationic material is minimized. As an example, I’ll focus on the concept of SS-cleavable and pH-activated lipid-like materials (ssPalm), that are designed to collapse in response to the intracellular environment to accelerate the “decapsulation/release” of nucleic acids (DNA and siRNA). \\r\\nAs another strategy, I’ll propose a particle that mounts a “Switch-on” function as a trigger of signal transduction, and stimulation of transcription. As an example, I’ll summarize the dendritic cell-targeted gene delivery for the DNA vaccine.\\r\\n\\r\\n
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 9 Nov 2018
The promise of cell-based gene therapies using non-viral delivery approaches
Conference abstract · 2 Oct 2017
Dynamic combinatorial approch as synthetic strategy for the formation of non-viral vectors for gene therapy.
Conference abstract · 25 Nov 2013
Development of high sensitivity flow cytometry for the advanced characterization of viral & non-viral drug delivery systems
Commentary · 31 Jul 2024
Viral and Non-viral Delivery Systems for Gene Therapy: Clinical Applications
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectGenetics & Molecular Biology
- SubjectInfectious Diseases
- SubjectNanotechnology
- BylineArticles whose byline prints “Hidetaka Akita”
